Compugen Ltd.
CGENNext catalyst
COM701
Ovarian Cancer
Get an email about CGEN's next catalysts
Track Compugen (CGEN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, data readout).See the timeline
3 upcoming, 0 past
CGEN Earnings Report
EPS Est: $-0.08 | FQ end Sep/2026 | Call: bmo
COM701 Phase 2 Est. Readout (MAIA-ovarian)
Primary completion for COM701 trial (NCT06888921) in Ovarian Cancer
SourceData Readout — COM701
For ovarian cancer. Compugen reported Q2 2026 results with COM701 MAIA-ovarian trial progressing as planned. Median progression-free survival data from the interim analysis is expected by Q1 2027.
SourceMarket Overview
Stock performance and key metrics
Compugen Ltd. (Hebrew: קומפיוג'ן) is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
COM701 | Phase 2 | Ovarian Cancer | - | - |
Frequently asked questions
What is in Compugen Ltd.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Compugen Ltd.'s (CGEN) pipeline across Phase 2. Its lead program is COM701 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Compugen Ltd.'s next FDA catalyst?→
Compugen Ltd.'s (CGEN) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CGEN biotech catalysts?→
Add CGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Compugen Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.